{
    "organizations": [],
    "uuid": "1d4973c6be148a46e3d52435d29c9c379c8d58b5",
    "author": "",
    "url": "https://www.reuters.com/article/brief-alnylam-receives-european-medicine/brief-alnylam-receives-european-medicines-agency-prime-designation-for-accelerated-assessment-of-lumasiran-idUSFWN1R80DU",
    "ord_in_thread": 0,
    "title": "BRIEF-Alnylam Receives European Medicines Agency Prime Designation For Accelerated Assessment Of Lumasiran",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 22 AM / Updated 12 minutes ago BRIEF-Alnylam Receives European Medicines Agency Prime Designation For Accelerated Assessment Of Lumasiran Reuters Staff 1 Min Read   Alnylam Pharmaceuticals Inc: * ALNYLAM RECEIVES EUROPEAN MEDICINES AGENCY PRIME DESIGNATION FOR ACCELERATED ASSESSMENT OF LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1) * ALNYLAM PHARMACEUTICALS INC - COMPANY INTENDS TO ADVANCE LUMASIRAN TO A PHASE 3 STUDY IN LATE 2018 Source text for Eikon: Further company coverage:",
    "published": "2018-03-26T14:21:00.000+03:00",
    "crawled": "2018-03-26T14:43:11.003+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "updated",
        "minute",
        "ago",
        "receives",
        "european",
        "medicine",
        "agency",
        "prime",
        "designation",
        "accelerated",
        "assessment",
        "lumasiran",
        "reuters",
        "staff",
        "min",
        "read",
        "alnylam",
        "pharmaceutical",
        "inc",
        "alnylam",
        "receives",
        "european",
        "medicine",
        "agency",
        "prime",
        "designation",
        "accelerated",
        "assessment",
        "lumasiran",
        "investigational",
        "rnai",
        "therapeutic",
        "treatment",
        "primary",
        "hyperoxaluria",
        "type",
        "ph1",
        "alnylam",
        "pharmaceutical",
        "inc",
        "company",
        "intends",
        "advance",
        "lumasiran",
        "phase",
        "study",
        "late",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}